Tizona Lands AbbVie Cancer R&D Deal As New CEO Takes Control

California-based Tizona has begun 2019 by installing a new CEO and winning a lucrative early-stage R&D pact with AbbVie aimed at commercializing cancer therapies targeting the immune system-suppressing enzyme CD39.

ScienceLab
Tizona and AbbVie hope to develop and commercialize CD39-targeted therapeutics • Source: Shutterstock

Privately-held biopharma Tizona Therapeutics Inc. got its New Year off to a good start by unveiling an early-stage cancer R&D collaboration with AbbVie Inc. by which the San Francisco-based biotech will receive a $105m upfront cash payment plus an equity injection from the big pharma.

News of the R&D pact - aimed at inhibiting the activity of CD39 - coincides with the arrival at Tizona...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip